Clinical Research Directory
Browse clinical research sites, groups, and studies.
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Sponsor: Context Therapeutics Inc.
Summary
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Official title: Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-03-31
Completion Date
2028-12
Last Updated
2026-06-12
Healthy Volunteers
No
Conditions
Interventions
CT-95
MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant/physician decision.
Locations (9)
Context Investigational Site
Denver, Colorado, United States
Context Investigational Site
Chicago, Illinois, United States
Context Investigational Site
Grand Rapids, Michigan, United States
Context Investigational Site
Hackensack, New Jersey, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Context Investigational Site
Philadelphia, Pennsylvania, United States
Context Investigational Site
Nashville, Tennessee, United States
Context Investigational Site
San Antonio, Texas, United States
Context Investigational Site
San Antonio, Texas, United States